ICU Medical, Inc. (NASDAQ:ICUI) Shares Sold by Rhumbline Advisers

Rhumbline Advisers trimmed its stake in ICU Medical, Inc. (NASDAQ:ICUI) by 4.6% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 67,891 shares of the medical instruments supplier’s stock after selling 3,287 shares during the quarter. Rhumbline Advisers’ holdings in ICU Medical were worth $10,535,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. New York State Teachers Retirement System grew its holdings in shares of ICU Medical by 6.7% in the 4th quarter. New York State Teachers Retirement System now owns 28,343 shares of the medical instruments supplier’s stock worth $4,398,000 after acquiring an additional 1,777 shares during the last quarter. Equitable Trust Co. lifted its holdings in shares of ICU Medical by 1.6% during the fourth quarter. Equitable Trust Co. now owns 5,297 shares of the medical instruments supplier’s stock worth $822,000 after buying an additional 84 shares during the last quarter. Jennison Associates LLC bought a new stake in ICU Medical in the 4th quarter valued at $556,000. Gagnon Securities LLC grew its position in ICU Medical by 0.5% during the fourth quarter. Gagnon Securities LLC now owns 28,881 shares of the medical instruments supplier’s stock worth $4,481,000 after buying an additional 137 shares in the last quarter. Finally, OLD National Bancorp IN increased its position in shares of ICU Medical by 22.0% during the fourth quarter. OLD National Bancorp IN now owns 1,462 shares of the medical instruments supplier’s stock valued at $227,000 after purchasing an additional 264 shares during the period. Institutional investors own 96.10% of the company’s stock.

Insiders Place Their Bets

In other news, Director David C. Greenberg sold 972 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $158.11, for a total transaction of $153,682.92. Following the sale, the director now owns 5,037 shares in the company, valued at approximately $796,400.07. This represents a 16.18 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $162.91, for a total value of $1,954,920.00. Following the completion of the transaction, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at $17,039,245.63. This represents a 10.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 15,775 shares of company stock valued at $2,548,017. 6.70% of the stock is currently owned by insiders.

ICU Medical Trading Down 3.5 %

Shares of ICU Medical stock opened at $157.42 on Monday. ICU Medical, Inc. has a 12-month low of $93.36 and a 12-month high of $196.26. The stock has a market capitalization of $3.85 billion, a P/E ratio of -34.45 and a beta of 0.63. The company has a 50-day simple moving average of $160.74 and a 200 day simple moving average of $166.22. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75.

Analysts Set New Price Targets

A number of equities analysts have recently commented on ICUI shares. KeyCorp raised their price objective on shares of ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday, November 13th. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Wednesday, November 20th. Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a report on Wednesday, November 13th. Finally, Jefferies Financial Group raised ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 target price for the company in a report on Wednesday, December 11th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, ICU Medical presently has an average rating of “Moderate Buy” and an average price target of $199.67.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.